Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy

Key facts

Sponsor

Byron Lam

Principal Investigator

Byron Lam, MD

Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL 33136

Intervention

injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),(drug)

Enrollment

28 enrolled

Eligibility

15 years · All sexes

Timeline

2014 – 2025

Study locations (1)

• Bascom Palmer Eye Institute, University of Miami, Miami, Florida, United States

Collaborators

National Eye Institute (NEI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hereditary optic neuropathy

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2, PHASE3NCT04912843
  Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy
  Wuhan Neurophth Biotechnology Limited Company

See all trials for Hereditary optic neuropathy →